Banlota, Daisy A.

HRN: 15-36-30  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/14/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
07/14/2024
07/21/2024
IV
1.5g
Q6h
Breast Mass, Invasive Ductal Carcinoma
Waiting Final Action 
07/14/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/14/2024
07/21/2024
IV
600mg
Q8h
Breast Mass, Invasive Ductal Carcinoma
Waiting Final Action 
07/14/2024
MUPIROCIN 2%, 15G (TUBE)
07/14/2024
07/21/2024
TOPICAL
Appli Thinly
BID
Breast Mass, Invasive Ductal Carcinoma
Waiting Final Action 
07/15/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
07/15/2024
07/22/2024
IV
4.5g
Q8
Breast Mass
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: